patients presenting with acute myocardial infarction are at increased risk of heart failure and death sodium glucose co-transporter 2 Inhibitors improve cardiovascular outcomes in high-risk patients with diabetes chronic kidney disease or heart failure but their effects following acute MI are unknown a new trial assessed the benefits and risks of the sglt2 inhibitor empig loin in patients with acute MI and an increased risk of heart failure in this International event-driven doubleblind randomized trial 6522 adults who had been hospitalized with acute MI and had either a newly developed left ventricular ejection fraction below 45% or signs or symptoms of congestion requiring treatment or both Plus at least one additional factor that was known to be associated with hospitalization for heart failure or death from any cause were assigned to receive Mosin at a dose of 10 Mig daily or Placebo plus standard care the primary endpoint was a composite of hospitalization for heart failure or death from any cause as assessed in a time to first event analysis during a median followup of approximately 18 months the percentage of patients with a primary endpoint event did not differ signific iFly between the groups occurring in 88. 2% of Igan recipients and 9. 1% of placebo recipients a first hospitalization for heart failure occurred in 3.
6 and 4. 7% of participants respectively and death from any cause occurred in 5. 2 and 5.
5% the percentage of patients with serious Adverse Events was similar in the two groups the authors conclude that in patients at increased risk of heart failure following acute MI empen did not lead to a significantly lower risk of the composite endpoint of a first hospitalization for heart failure or death from any cause than Placebo full trial results are available at nj.
